Routine Coronary Atherosclerosis Imaging in the Cardiovascular Risk Assessment of Prediabetes and Diabetes

糖尿病前期 医学 糖尿病 内科学 心脏病学 冠状动脉粥样硬化 冠状动脉疾病 2型糖尿病 内分泌学
作者
Thiago Bosco Mendes,Márcio Sommer Bittencourt
出处
期刊:Circulation-cardiovascular Imaging [Ovid Technologies (Wolters Kluwer)]
卷期号:16 (10)
标识
DOI:10.1161/circimaging.123.016079
摘要

HomeCirculation: Cardiovascular ImagingVol. 16, No. 10Routine Coronary Atherosclerosis Imaging in the Cardiovascular Risk Assessment of Prediabetes and Diabetes No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextRoutine Coronary Atherosclerosis Imaging in the Cardiovascular Risk Assessment of Prediabetes and Diabetes Thiago Bosco Mendes and Marcio Sommer Bittencourt Thiago Bosco MendesThiago Bosco Mendes Department of Medicine, University of Pittsburgh Medical Center, PA (T.B.M., M.S.B.). Search for more papers by this author and Marcio Sommer BittencourtMarcio Sommer Bittencourt Correspondence to: Marcio Sommer Bittencourt, MD, MPH, PhD, UPMC Presbyterian Hospital, Suite A-429, 200 Lothrop St, Pittsburgh, PA 15213. Email E-mail Address: [email protected] https://orcid.org/0000-0002-3711-1754 Department of Medicine, University of Pittsburgh Medical Center, PA (T.B.M., M.S.B.). University of Pittsburgh Medical School, PA (M.S.B.). Search for more papers by this author Originally published29 Sep 2023https://doi.org/10.1161/CIRCIMAGING.123.016079Circulation: Cardiovascular Imaging. 2023;16This article is a commentary on the followingCoronary Atherosclerosis Across the Glycemic Spectrum Among Asymptomatic Adults: The Miami Heart Study at Baptist Health South FloridaFootnotesFor Disclosures, see page 805.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Marcio Sommer Bittencourt, MD, MPH, PhD, UPMC Presbyterian Hospital, Suite A-429, 200 Lothrop St, Pittsburgh, PA 15213. Email msbittencourt@mail.harvard.eduREFERENCES1. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey.Diabetes Care. 2005; 28:1588–1593. doi: 10.2337/diacare.28.7.1588CrossrefMedlineGoogle Scholar2. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis.Diabet Med. 2009; 26:142–148. doi: 10.1111/j.1464-5491.2008.02640.xCrossrefMedlineGoogle Scholar3. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study.Circulation. 2009; 120:212–220. doi: 10.1161/CIRCULATIONAHA.108.846519LinkGoogle Scholar4. Raggi P. Screening for atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: controversies and guidelines.Can J Diabetes. 2020; 44:86–92. doi: 10.1016/j.jcjd.2019.08.009CrossrefMedlineGoogle Scholar5. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes—2023.Diabetes Care. 2023; 46(supplement_1):S158–S190. doi: 10.2337/dc23-S010CrossrefMedlineGoogle Scholar6. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.Circulation. 2019; 140:e596–e646. doi: 10.1161/CIR.0000000000000678LinkGoogle Scholar7. Muhlestein JB, Lappé DL, Lima JAC, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.JAMA. 2014; 312:2234–2243. doi: 10.1001/jama.2014.15825CrossrefMedlineGoogle Scholar8. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med. 2007; 356:1503–1516. doi: 10.1056/NEJMoa070829CrossrefMedlineGoogle Scholar9. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, et al; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease.N Engl J Med. 2020; 382:1395–1407. doi: 10.1056/NEJMoa1915922CrossrefMedlineGoogle Scholar10. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al; LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2016; 375:311–322. doi: 10.1056/NEJMoa1603827CrossrefMedlineGoogle Scholar11. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu X-F, Ireland MA, Lenderink T, et al; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease.N Engl J Med. 2020; 383:1838–1847. doi: 10.1056/NEJMoa2021372CrossrefMedlineGoogle Scholar12. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease.N Engl J Med. 2017; 377:1319–1330. doi: 10.1056/NEJMoa1709118CrossrefMedlineGoogle Scholar13. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N Engl J Med. 2019; 380:11–22. doi: 10.1056/NEJMoa1812792CrossrefMedlineGoogle Scholar14. Patel KV, Budoff MJ, Valero-Elizondo J, Ali SS, Havistin R, Lakshman S, Blaha MJ, Blankstein R, Shapiro MD, Arias L, et al. Coronary atherosclerosis across the glycemic spectrum among asymptomatic adults: the Miami Heart Study at Baptist Health South Florida.Circ Cardiovasc Imaging. 2023; 16:e015314. doi: 10.1161/CIRCIMAGING.123.015314LinkGoogle Scholar15. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med. 2008; 358:580–591. doi: 10.1056/nejmoa0706245CrossrefMedlineGoogle Scholar16. Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus.Circulation. 2016; 134:1579–1594. doi: 10.1161/CIRCULATIONAHA.116.023164LinkGoogle Scholar17. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects.J Am Coll Cardiol. 2016; 67:2395–2410. doi: 10.1016/j.jacc.2016.02.071CrossrefMedlineGoogle Scholar18. Study Group ACCORD, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus.N Engl J Med. 2010; 362:1575–1585. doi: 10.1056/NEJMoa1001286CrossrefMedlineGoogle Scholar19. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2018; 379:633–644. doi: 10.1056/NEJMoa1800256CrossrefMedlineGoogle Scholar20. Magnussen C, Ojeda FM, et al; Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality [published online August 26, 2023].N Engl J Med. 2023. doi: 10.1056/NEJMoa2206916. Epub ahead of print. PMID: 37632466.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCoronary Atherosclerosis Across the Glycemic Spectrum Among Asymptomatic Adults: The Miami Heart Study at Baptist Health South FloridaKershaw V. Patel, et al. Circulation: Cardiovascular Imaging. 2023;16 October 2023Vol 16, Issue 10 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCIMAGING.123.016079PMID: 37772410 Originally publishedSeptember 29, 2023 KeywordsEditorialscardiovascular diseasescoronary artery diseaseearly diagnosishumansPDF download Advertisement SubjectsCardiovascular DiseaseDiabetes, Type 2EpidemiologyPrimary PreventionRisk Factors
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
肾小球呵呵完成签到,获得积分10
刚刚
Lina发布了新的文献求助10
刚刚
4秒前
天御雪完成签到,获得积分10
5秒前
cr完成签到,获得积分20
8秒前
8秒前
闪闪的海蓝完成签到,获得积分10
9秒前
秦始皇1完成签到,获得积分10
9秒前
9秒前
Lina完成签到,获得积分10
10秒前
kang发布了新的文献求助10
10秒前
cr发布了新的文献求助10
13秒前
秦始皇1发布了新的文献求助10
14秒前
小居很哇塞完成签到,获得积分10
15秒前
华仔应助石烟祝采纳,获得10
16秒前
16秒前
在水一方应助牧青采纳,获得10
19秒前
19秒前
21秒前
21秒前
MISSIW完成签到,获得积分10
23秒前
怡然的友容完成签到,获得积分10
23秒前
阜睿发布了新的文献求助10
26秒前
轩辕白竹完成签到,获得积分10
28秒前
sdndkjfvb关注了科研通微信公众号
29秒前
小糊涂完成签到 ,获得积分10
29秒前
王忠凯发布了新的文献求助10
30秒前
rocky15应助青青草采纳,获得10
31秒前
34秒前
苗条丹南完成签到 ,获得积分10
37秒前
40秒前
凉翊完成签到,获得积分10
41秒前
41秒前
科目三应助青青草采纳,获得10
43秒前
脑洞疼应助十七采纳,获得10
44秒前
方静怡发布了新的文献求助10
45秒前
上官若男应助科研通管家采纳,获得30
45秒前
天天快乐应助科研通管家采纳,获得10
45秒前
45秒前
影像大侠应助肖旻采纳,获得10
45秒前
高分求助中
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2547030
求助须知:如何正确求助?哪些是违规求助? 2176077
关于积分的说明 5602154
捐赠科研通 1896805
什么是DOI,文献DOI怎么找? 946415
版权声明 565383
科研通“疑难数据库(出版商)”最低求助积分说明 503687